H. Shimizu

发表

A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-host disease by National Institutes of Health Criteria in a Japanese cohort.

H. Nakasone, Y. Kanda, Jun Kato, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma

Y. Najima, T. Shimoyama, Y. Omuro, 2021, Medicine.

Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation

K. Ohashi, H. Sakamaki, Y. Najima, 2022, Scientific Reports.

Additional Cytogenetic Abnormalities with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia on Allogeneic Stem Cell Transplantation in the Tyrosine Kinase Inhibitor Era.

S. Kako, K. Ohashi, M. Onizuka, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades

Takafumi Kimura, M. Onizuka, Satoshi Takahashi, 2022, Blood advances.

Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre‐transplant conditioning using fludarabine, reduced‐dose cyclophosphamide, and low‐dose thymoglobulin: A KSGCT prospective study

S. Kako, Y. Kanda, Jun Kato, 2019, American journal of hematology.

Autologous hematopoietic cell transplantation for myeloma patients with hepatitis B virus or hepatitis C virus in the era of novel agents

I. Hanamura, S. Iida, K. Kawamura, 2022, Bone Marrow Transplantation.

Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation

H. Nakasone, S. Kimura, Y. Kanda, 2022, Bone Marrow Transplantation.

Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission

S. Kako, Y. Kanda, Jun Kato, 2021, Bone Marrow Transplantation.

Central nervous system mucormycosis in a patient with hematological malignancy: A case report and review of the literature.

N. Funata, T. Hishima, S. Horiguchi, 2022, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine

M. Onizuka, Takehiko Mori, Y. Koda, 2020, International Journal of Hematology.

Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia

K. Ohashi, Y. Najima, H. Harada, 2022, Leukemia & lymphoma.

Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Study in Japan.

Y. Kanda, Y. Kodera, H. Tamaki, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes

K. Ohashi, Y. Najima, H. Harada, 2023, Scientific Reports.

Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality.

H. Nakasone, S. Kimura, Y. Kanda, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia with Pre-Transplant Conditioning Using Fludarabine, Reduced-Dose Cyclophosphamide, and Low-Dose Thymoglobulin:Â Ksgct Prospective Study

S. Kako, Y. Kanda, M. Onizuka, 2018, Blood.

Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study

K. Ohashi, Y. Najima, S. Kito, 2022, Annals of medicine.

Phase I trial of myeloablative conditioning with 3‐day total marrow and lymphoid irradiation for leukemia

K. Ohashi, Y. Najima, S. Kito, 2022, Cancer science.

Donor‐derived gene mutations in sex chromosome loss after stem cell transplantation

K. Ohashi, H. Sakamaki, Y. Najima, 2021, British journal of haematology.

Novel indicators of transplant outcomes for PhALL: "current molecular-relapse-free survival".

S. Fujiwara, H. Nakasone, R. Yamazaki, 2021, Transplantation and Cellular Therapy.

Successful Cord Blood Transplantation for Idiopathic CD4+ Lymphocytopenia

K. Ohashi, H. Sakamaki, Y. Najima, 2021, Acta Haematologica.

Attenuated humoral response against SARS‐CoV‐2 mRNA vaccination in allogeneic stem cell transplantation recipients

M. Kohara, K. Ohashi, Y. Najima, 2022, Cancer science.

A third dose of COVID‐19 mRNA vaccine induces limited humoral response in stem cell transplant recipients who got two vaccine doses before transplant

M. Kohara, Y. Najima, Y. Harada, 2022, EJHaem.

Low-Grade B-cell Malignancy with M-Protein and Autoimmune Cytopenia

H. Shimizu, Y. Miyazawa, Manato Sugisaki, 2022, The Kitakanto Medical Journal.

Prognostic factors for the development of lower respiratory tract infection after influenza virus infection in allogeneic hematopoietic stem cell transplantation recipients: A KSGCT Multicenter Analysis.

Y. Kanda, M. Onizuka, Satoshi Takahashi, 2023, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.